Concomitant Treatment of Chronic Hepatitis C With Direct-Acting Antivirals and Multidrug-Resistant Tuberculosis Is Effective and Safe.

Auteurs: Melikyan N Huerga H Atshemyan H Kirakosyan O Sargsyants N Aydinyan T Saribekyan N Khachatryan N Oganezova I Falcao J Balkan S Hewison C
Référence de l'article: Open forum infectious diseases 2021 Feb ; 8(2); ofaa653. doi: 10.1093/ofid/ofaa653. Epub 2021 01 04
chronic hepatitis C direct-acting antiviral drugs multidrug-resistant tuberculosis sofosbuvir virus


We assessed effectiveness and safety of concomitant chronic hepatitis C virus (HCV) treatment with direct-acting antivirals (DAAs) and multidrug-resistant tuberculosis (MDR-TB). Of 322 MDR-TB patients (19.4% HCV), 30 were treated concomitantly (23.3% human immunodeficiency virus-positive). Overall, 76.7% achieved HCV treatment success (95.8% among tested). One patient (3.3%) experienced a serious adverse event.

© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.